What is Amide Technologies?
Amide Technologies specializes in advanced peptide synthesis, leveraging its innovative AFPS technology to produce complex peptides that are challenging to create through conventional methods. The company aims to bridge the gap between traditional synthesis and biological expression, offering reliable synthesis of linear peptides up to 120 amino acids with rapid turnaround times. Their core focus is on supporting the drug development sector by providing urgent peptide orders to accelerate design-build-test cycles, thereby facilitating the discovery of novel therapeutic modalities.
How much funding has Amide Technologies raised?
Amide Technologies has raised a total of $11.5M across 1 funding round:
Series A
$11.5M
Series A (2023): $11.5M with participation from The Engine
Key Investors in Amide Technologies
The Engine
The Engine, built by MIT, is a venture firm investing in the next generation of Tough Tech, focusing on transformative approaches to solve challenges in human health, climate change, and advanced systems and infrastructure. Their investment in Amide Technologies suggests a strategic alignment with advancements in human health and therapeutic development.
What's next for Amide Technologies?
With its recent Series A financing, Amide Technologies is poised for significant expansion. The substantial enterprise-level funding indicates a strong market validation and provides the necessary capital to scale its operations, enhance its AFPS technology, and broaden its service offerings to the burgeoning drug development and biotechnology industries. This strategic backing will likely fuel advancements in peptide synthesis capabilities, enabling the company to tackle increasingly complex projects and solidify its position as a key player in the therapeutic discovery ecosystem.
See full Amide Technologies company page
